Influenza: Oral tablet vaccine shows promise in Phase 2 challenge study
by Press Release from Outbreak News Today on (#36HTK)
Vaxart, Inc., a privately-held, clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that its H1 influenza oral tablet vaccine demonstrated similar protection against influenza virus as the market-leading injectable quadrivalent influenza vaccine (QIV) in a clinical trial. These results met the efficacy objectives of the Phase ["]
The post Influenza: Oral tablet vaccine shows promise in Phase 2 challenge study appeared first on Outbreak News Today.